Grupo Vet News

It is important to distinguish between the API and the finished drug product. Atorvastatin API is a pure, bulk chemical powder produced by specialized chemical manufacturers.

It is not for direct use by patients. To become a medicine, a pharmaceutical company must take this API and mix it with other inactive ingredients—such as fillers, binders, and coatings—to create a stable tablet or capsule. These finished products are what you find in a pharmacy under brand names like Lipitor or various generic versions. The quality and purity of the initial API are the most vital factors in determining how effective the final medicine will be.

One of the most visible shifts in 2026 is the movement away from bulky boxes and tangles of wires toward Patch-Based Telemetry.

• Wireless Patches: These are single-use, waterproof adhesive patches that contain the sensors, processor, and battery in one unit. They eliminate the "cheese-cutter" effect of wires and allow patients to shower while being monitored.

• Lead-Based Systems: Despite the rise of patches, traditional 5-lead systems remain the gold standard for high-acuity patients where advanced 12-lead ECG analysis is required to detect complex arrhythmias or specific ischemia (reduced blood flow).

• Multi-Parametric Monitoring: Beyond ECG, modern telemetry units now incorporate Continuous SpO2 (blood oxygen), Respiratory Rate, and Non-Invasive Blood Pressure (NIBP), all transmitted through the same wireless link.

FNA is the least invasive biopsy method, often used to distinguish between solid masses and fluid-filled cysts.

• Procedure: A very thin, hollow needle (similar to those used for blood draws) is inserted into the lump.

• Utility: If the lump is a cyst, the fluid is drained, and the lump typically disappears, providing both diagnosis and treatment.

• Limitations: Because FNA only collects a small number of cells rather than a solid piece of tissue, it may not provide enough information to determine the "invasiveness" of a cancer if one is found.

A major innovation in 2026 is the widespread adoption of Non-Metallic Suture Tapes, such as the FiberTape system. These are composed of ultra-high molecular weight polyethylene (UHMWPE) and offer a "middle ground" between traditional wires and expensive plates.

The primary benefit of suture tapes is their Surface Area. Because the tape is flat and wide (typically 2mm), it distributes force over a larger area of the bone compared to thin metal wires. This significantly reduces the risk of the material cutting through the sternum. Clinical data from 2025 and 2026 indicates that suture tapes result in significantly lower pain scores at 14 and 30 days post-surgery and can reduce the total closure time by up to 40% compared to complex wiring techniques.